TAP Sleep Care's Dual Therapy: Mouth Shield + TAP Enhances Health in Sleep Apnea
Dual Therapy: Mouth Shield + TAP Improves Sleep Apnea Health

TAP Sleep Care's Dual Therapy: Mouth Shield + TAP Enhances Health in Sleep Apnea

DALLAS, Feb. 24, 2026 — TAP Sleep Care, powered by Airway Management, has announced groundbreaking clinical research highlighting the benefits of dual therapy using the patented Mouth Shield with TAP devices. This innovative approach combines the TAP device, which advances the lower jaw to treat sleep apnea, with a silicone Mouth Shield that seals the mouth to promote nasal breathing and reduce snoring.

Comprehensive Health Benefits

This dual therapy supports periodontal health, delivers promising acute improvements in cardiac electrophysiology and hemodynamics, and offers potential cognitive enhancements for patients with obstructive sleep apnea (OSA) and comorbidities such as paroxysmal atrial fibrillation (AF) or cognitive concerns. Three peer-reviewed studies from 2025 and a key pilot study demonstrate these advantages.

Key Study Findings

  • Periodontal Health Study: A 2025 split-mouth randomized controlled trial in Dentistry Journal involved 14 adults with mild-to-moderate periodontitis who snored and mouth-breathed. Over 12 weeks, combining standard gum treatment with myTAP + Mouth Shield dual therapy resulted in significant reductions in snoring, mouth breathing, and respiratory disturbance index. It also improved gum health with less bleeding and reduced harmful bacteria, with no short-term negative effects on gums or teeth.
  • Cardiac Health Case Report: Published in Frontiers in Sleep in 2025, this study focused on a 67-year-old man with moderate OSA and recurring paroxysmal AF. Dual therapy yielded a 61.9% reduction in premature atrial contractions, improved cardiac conduction intervals, and enhanced vascular function, outperforming auto-adjusting positive airway pressure (APAP) and suggesting promise for OSA patients with AF.
  • Cognitive Improvement Pilot Study: A 2021 study in Geriatrics found that oral appliance therapy with a mouth shield led to cognitive improvements in older adults with snoring, including those with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Results showed stabilized breathing patterns mitigating OSA-related sleep fragmentation and hypoxia for better brain health.

Expert Insights and Clinical Support

"The dual therapy approach with the Mouth Shield and TAP devices is transforming sleep care by addressing not just OSA symptoms but also gum disease, heart rhythm issues, and cognitive decline," said Charles Collins, CEO of Airway Management. "As clinicians and patients seek user-friendly alternatives to CPAP—due to comfort, adherence, and lifestyle challenges—these studies highlight real benefits: better nasal breathing, reduced snoring and dry mouth, healthier gums, improved cognition, and potential cardiac support—in a comfortable, non-invasive design."

Backed by over 50 independent peer-reviewed studies on TAP devices and aligned with guidelines from the American Academy of Sleep Medicine (AASM) and American Academy of Dental Sleep Medicine (AADSM), this evidence-based solution delivers high patient compliance through its customizable, silent format.

Invitation for Further Exploration

TAP Sleep Care invites individuals with snoring, mouth breathing, OSA, periodontal issues, cognitive concerns, or cardiac comorbidities to explore dual therapy. For more information, including provider locators and full study details, visit tapintosleep.com.

Press inquiries can be directed to Kelly Grant, Marketing, at kgrant@amisleep.com or toll-free at 866-264-7667.